Upadacitinib taken once daily as a pill significantly improved eczema symptoms compared to placebo, with 70% of patients on the 15mg dose and 80% on the 30mg dose showing major improvement in their eczema after 16 weeks.
-
Once-daily upadacitinib versus placebo in adolescents and adults with moderate-to-severe atopic dermatitis (Measure Up 1 and Measure Up 2): results from two replicate double-blind, randomised controlled phase 3 trials
Once-daily upadacitinib versus placebo in adolescents and adults with moderate-to-severe atopic dermatitis (Measure Up 1 and Measure Up 2): results from two replicate double-blind, randomised controlled phase 3 trials
TBD
DOI: 10.1016/S0140-6736(21)00588-2
Randomized Controlled Trial
•
847 participants
•
2024
•
248 citations
-
What is this paper about?
-
How did the authors study this?
Study was conducted through a randomized controlled trial (RCT). RCTs are considered the gold standard for drawing evidence-based conclusions.
-
What populations did the authors study?
Adolescents (12-17 years) and adults (18-75 years) with moderate-to-severe atopic dermatitis
-
What did the authors find?
EASI-75: % of patients achieving 75% or greater improvement in Eczema Area and Severity Index
vIGA-AD response: % of patients achieving clear or almost clear skin with at least 2 grades of improvement
